New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

New data finds women 8% more likely to experience major complications after transcatheter aortic valve implantation (TAVI) ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms.

It’s no surprise that complications can vex concomitant procedures. But when staged, should PCI or TAVI come first?

It is important to assess inflation and deflation timings at balloon insertion and on a regular basis whilst the balloon is in situ to avoid any related complications (see Table 1, Figure 7).

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

Edwards Lifesciences (NYSE: EW) received FDA approval for its Sapien 3 TAVR for severe aortic stenosis (AS) without symptoms.

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that ...